Amgen AMGN will report first-quarter 2025 results on May 1, after market close. In the last reported quarter, the company ...

Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

CuraTeQ Biologics s.r.o., announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending marketing authorisation of Dazublys®, its trastuzumab biosimilar, for the ...

Here are the top 5 biosimilar articles for the week of April 21, 2025. Number 5: Trastuzumab biosimilars saw significant ...

South Korea’s Samsung Bioepis today released its Second Quarter 2025 Biosimilar Market Report, which provides the second ...

The first wave of Stelara (ustekinumab) biosimilars show steep Wholesale Acquisition Cost discounts greater than 80%, the report finds.

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

Learn more about whether Alvotech or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

Prescription drugs continue to be the fastest-rising cost to many employer-sponsored health plans. A major driver of those ...

The company posted adjusted earnings of $2.77 per share on revenue of $21.9 billion, exceeding consensus estimates of $2.59 ...

J&J JNJ began the first-quarter earnings season for the drug and biotech sector with better-than-expected results. J&J’s ...